Skip to main content
. 2024 Oct 3;24:1171. doi: 10.1186/s12903-024-04938-8

Table 2.

The characteristics of included studies

Authors, year Country Funding information Type of Study Study settings Sample size(n) age M/F ratio
Adali et al. [38] Turkey None declared RCT Ege University 10 57 8 M/2F
Amam et al. [39] Syria None declared RCT Damascus University, 9 45–70 NA
Anitua et al. [40] Spain Basque and Spanish governments CCT Spain 5 NR 2 M/3F
Batas et al. [41] Greece None declared RCT Aristotle University C: 6 T: 6 NR NR
Bolukbasi et al. [42] Turkey None declared CCT Istanbul University 25

T: 50.06 ± 12.15

C: 47.43 ± 8.2

 10 M/15F
Bosshardt et al. [43] Switzerland None declared CCT University of Geneva T: 5 C: 3 41–64 1 M/7F
Cabbar et al. [18] Turkey None declared CCT Yeditepe University 10 53.7 ± 0.8 7 M/3F
Cho et al. [44] Korea Hanyang University RCT

Hanyang University Hospital and Apsun

Dental Hospital

 40 T: 46.8 C: 44.4 21 M/19F
Choukroun et al. [45] France None declared CCT France 9 NR NR
Cömert et al. [46] Turkey Ataturk University RCT Ataturk University 26 A: 9 B: 8 C: 9

A: 34.01 ± 9.59

B:35.48 ± 9.53

C: 31.51 ± 8.52

A:5 M/4F

B:5 M/3F

C:7 M/2F
de et al. [47] Brazil Coordenação de Aperfeiçoamento de Pessoal de Nível Superior RCT School of Dentistry at Araraquara 24 54.08 ± 10.07 10 M/14F
Gassling et al. [48] Germany The author’s institution RCT University Hospital of Schleswig-Holstein 6 61 NA
Jia et al. [49] China Peking University School and Hospital of Stomatology RCT Peking University Hospital of Stomatology 23 T: 51.1 ± 10.2 C: 49.1 ± 10.2 12 M/11F
Kanayama et al. [50] Japan None declared CCT Nagoya City University Hospital 27 54.2 12 M/15F
Karagah et al. [51] Iran No external funding RCT Qazvin University of Medical Sciences 10 48.3 ± 8.31 3 M/7F
Kassolis et al. [52] USA None declared CCT University of Maryland Dental School 10 NR NR
Kiliç et al. [53] Turkey Atatürk University RCT Atatürk University 18

T: 34.01 ± 9.59

C: 31.51 ± 8.52

T:5 M/4F

C:7 M/2F
Lv et al. [54] China National Nature Science Foundation of China and Key Scientific and Technological Projects of Jilin Province, China RCT Stomatology Hospital of Jilin University 40 A: 51.00 B: 54.50 18 M/22F
Molemans et al. [55] Belgium None declared CCT Stomatology Hospital of Jilin University 26 55 ± 10.1 14 M/12F
Nizam et al. [56] Turkey None declared RCT Ege University 13 49.92 ± 10.37 9 M/4F
Olgun et al. [57] Turkey Kirikkale University RCT Kirikkale University 18 T: 51 ± 7.94 C: 53 ± 8.96 9 M/9F
Pichotano et al. [58] Brazil Geistlich Pharma AG; Neodent; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior RCT São Paulo State University 12 54.17 ± 6.95 6 M/6F
Poeschl et al. [59] Austria None declared CCT Medical University of Vienna 25 26–82 NR
Raghoebar et al. [60] Netherlands None declared CCT University Hospital Groningen 5 58.4 ± 1.9 2 M/3F
Taschieri et al. [61] Italy None declared CCT Dental Clinic of the IRCCS Istituto Ortopedico Galeazzi T: 5 C: 5 48–71 2 M/4F
Tatullo et al. [62] Italy None declared RCT University of Bari, the Dental Clinic “Calabrodental” and the Institute of Research “Tecnologica” 60 T: 30 C: 18 Split mouth: 12 43–62 12 M/48F
Thor et al. [63] Sweden None declared CCT Stockholm Söder Hospital 19 58 2 M/17F
Thor et al. [31] Sweden None declared CCT Uppsala University Hospital 11 33–72 1 M/10F
Torres et al. [64] Spain the Ministry of Science and Technology, the UCM Programme for Research Groups, and the Spanish Agency of International Cooperation RCT The dental clinic “Clinica Dental Alcala” 87 52–78 40 M/47F
Zhang et al. [65] China None declared RCT Peking University 11

T: 43.5

C: 46.2

 8 M/2F
Authors, year platelet concentrate category type of bone filler used the number of sinuses Sinus Lift Complications the number of implants Implant Surgery
Adali et al. [38] CGF allogenic bone material 20 T: 0 C: 0 20 6 months after sinus lifting
Amam et al. [39] A-PRF CS (on one side) TCP (on the other side) 18 NR NR NR
Anitua et al. [40] PRGF Bio-Oss 10 T: 0 C: 0 NR NR
Batas et al. [41] PRGF Bio-Oss 12 T: 0 C: 0 NR NR
Bolukbasi et al. [42] PRF bovine bone graft T: 17 C: 15 T: 0 C: 0 T: 34 C: 32 6 months after sinus lifting
Bosshardt et al. [43] PRF Synthetic nanocrystalline hydroxyapatite embedded in highly porous silica gel matrix 12 T: 8 C: 4 T:0 C:0 16 7–11 months after sinus lifting
Cabbar et al. [18] L-PRP USB 20 T: 2 C: 2 28 6 months after sinus lifting
Cho et al. [44] PRF None 40 T: 20 C: 20 T: 0 C: 0 45 Immediate
Choukroun et al. [45] PRF FDBA T: 6 C: 3 T: 1 C: 0 NR T: 4 months after sinus lifting C: 8 months after sinus lifting
Cömert et al. [46] P-PRP, PRF β-TCP NR A: 1 B: 2 C: 2 NR 6 months after sinus lifting
de et al. [47] LPRF DBBM 24 T: 0 C: 0 37 8 months after sinus lifting
Gassling et al. [48] PRP Bio-Oss T: 6 C: 6 NR 32 5 months after sinus lifting
Jia et al. [49] CGF Bovine-derived xenograft T: 10 C: 13 NR 38 Immediate
Kanayama et al. [50] PRF None A: 20 B: 19 T: 0 C: 0 A: 20 B: 19 Immediate
Karagah et al. [51] PRF FDBA 20 NR 20 Immediate
Kassolis et al. [52] PRP FDBA 20 NR NR NR
Kiliç et al. [53] PRP β-TCP 18 T: 9 C: 9 3 NR 6 months after sinus lifting
Lv et al. [54] PRF DBBM NR NR 57 Immediate
Molemans et al. [55] LPRF None 28 NR 29 Immediate
Nizam et al. [56] L-PRF DBBM T: 13 C: 13 T: 0 C: 0 T: 30 C: 28 6 months after sinus lifting
Olgun et al. [57] T-PRF Allografts T: 10 C: 8 T: 0 C: 0 37 T: 4 months after sinus lifting C: 6 months after sinus lifting
Pichotano et al. [58] L-PRF DBBM T: 12 C: 12 T: 0 C: 0 T: 19 C: 19 T: 4 months after sinus lifting C: 8 months after sinus lifting
Poeschl et al. [59] PRP collected bone and algae-derived hydroxyapatite 31 T: 18 C: 13 1 42 6–9 months after sinus lifting
Raghoebar et al. [60] PRP autologous bone graft from the iliac crest 10 1 30 3 months after sinus lifting
Taschieri et al. [61] P-PRP Bio-Oss 10 NR NR 6 months after sinus lifting
Tatullo et al. [62] PRF DBBM 72 T: 0 C: 0 240 Early: 20 Intermediate: 20 Late: 20
Thor et al. [63] PRP autologous bone graft from the iliac crest 38 NR 152 6 months after sinus lifting
Thor et al. [31] PRP autologous bone graft from the iliac crest 22 NR NR 3 months after sinus lifting
Torres et al. [64] P-PRP Bio-Oss 144 T: 74 C: 70 T: 3 C: 2 286 deferred in 57 sinuses and immediate in 87
Zhang et al. [65] PRF Bio-Oss 11 T: 6 C: 5 NR T:6 C:5 6 months after sinus lifting
Authors, year Baseline information Follow-up time(m) Intervention Implant survival the percentage of new bone soft-tissue area
Adali et al. [38] Residual bone height: about 1–3 mm 6 T: allograft + CGF C: allograft 100% T: 36.41% C: 35.49% NR
Amam et al. [39]

Mean bone height values (mm):

CS + A-PRF: 3.55 ± 2.13 TCP + A-PRF: 3.86 ± 1.73 CS/TCP + A-PRF: 3.71 ± 1.89

 6 CS + A-PRF (on one side) TCP + A-PRF (on the other side) NR NR NR
Anitua et al. [40] Residual bone height: 1–3 mm 5 T: Bio-Oss + PRGF C: Bio-Oss NR T: 24.9 ± 4.94 C: 8.3 ± 0.14 NR
Batas et al. [41] Residual bone height < 3 mm 6 T: Bio-Oss + PRGF C: Bio-Oss NR T: 35.6 ± 8.26 C: 37.8 ± 3.15 T: 34.69 ± 5.86 C: 34.88 ± 5.81
Bolukbasi et al. [42] Residual crest height < 5 mm 6

T: bovine bone graft + PRF

C: resorbable collagen membrane + bovine bone graft

 100% T: 35.0 ± 8.60 C: 32.97 ± 9.71 T: 30.63 ± 7.53 C: 33.94 ± 9.15
Bosshardt et al. [43] The vertical height of the residual ridge: <4 mm 7–11

T: Synthetic nanocrystalline hydroxyapatite embedded in highly porous silica gel matrix + PRF

C: Synthetic nanocrystalline hydroxyapatite embedded in highly porous silica gel matrix + collagen membrane

 NA T: 28.6 ± 6.9 C: 28.7 ± 5.4

T: 45.7 ± 9.3

C: 45.8 ± 3.2
Cabbar et al. [18] The mean height of the residual alveolar crest(mm): T: 4.7 ± 1.3 C: 5.6 ± 1.4 12-15.2 T: USB + L-PRP C: USB 92.9% T: 16.0 ± 3.8 C: 15.8 ± 4.8

T: 57.8 ± 4.4

C: 59.9 ± 7.5
Cho et al. [44] RABH (mm): T: 7.2 ± 1.1 C: 6.4 ± 1.1 6; 12 T: PRF C: saline 100% NR NR
Choukroun et al. [45] NR 6/8

T: FDBA + PRF

C: FDBA

 NR

T after 4 months: 20.95

C after 8 months: 20.31

 NR
Cömert et al. [46] Residual bone crest height: 7 mm or lesser 6

A: P-PRP + β-TCP

B: PRF + β-TCP

C: β-TCP

 NR A: 34.83 ± 10.1 B: 32.03 ± 6.3 C: 33.40 ± 10.4 A: 36.19 ± 13.9 B: 35.31 ± 10.8 C: 36.21 ± 10.6
de et al. [47] Residual height of the alveolar ridge: less than or equal to 4 mm 8 T: LPRF and DBBM C: DBBM 100% T: 46.56 ± 12.25 C: 32.34 ± 9.49 T: 17.76 ± 12.03 C: 28.29 ± 10.07
Gassling et al. [48] RABH < 5 mm 5

PRP (on one side)

collagen (on the other side)

 NR T: 17.0 C: 17.2 NR
Jia et al. [49] RABH (mm): T: 3.58 ± 1.49 C: 4.12 ± 1.61 12 T: CGF + bone window repositioning C: CGF 100% NR NR
Kanayama et al. [50] Residual bone height(mm): A: 2.85 ± 1.13 B: 2.68 ± 1.20 12

A: PRF + sandblasted acid-etched implant

B: PRF + hydroxyapatite implant

 100% NR NR
Karagah et al. [51] ISQ: FDBA: 53.25 ± 2.268 PRF: 53.00 ± 2.384 2; 4; 6 PRF (on one side) FDBA (on the other side) NR NR NR
Kassolis et al. [52]

Residual bone height:

T: 5.2 ± 2.2 C: 5.0 ± 3.2 mm

 2 T: FDBA + PRP C: FDBA + membrane NR T: 33.3 ± 1.3 C: 26.5 ± 6.8 NR
Kiliç et al. [53] Residual bone crest height: T: 2.70 ± 2.57 C: 4.88 ± 2.37 6

T: β-TCP + PRP

C: β-TCP

 NR NR NR
Lv et al. [54] Residual bone height: 2–6 mm 18

A: PRF + lapless endoscope-assisted osteotome SFE

B: deproteinised bovine bone matrix + lateral SFE

 A:96.15% B:100% NR NR
Molemans et al. [55]

Residual bone height (mm):

A: 6.1 ± 1.6 B: 4.6 ± 2.0

 6

A: transalveolar SFE + LPRF

B: lateral SFE + LPRF

 93.10% NR NR
Nizam et al. [56]

Residual bone height (mm):

T: 2.45 ± 0.79 C: 2.53 ± 0.61

 6 T: DBBM + L-PRF C: DBBM 100% T: 21.4 ± 8.8 C: 21.2 ± 5.6 T: 52.7 ± 12.5 C: 45.9 ± 8.4
Olgun et al. [57] Residual crest height of < 5 mm 6 T: T-PRF C: Allografts NR T: 16.6 ± 1.1 C: 17.3 ± 2.5 NR
Pichotano et al. [58] Residual bone height < 4 mm 4 for the test group and 8 for the control group T: DBBM + L-PRF C: DBBM 100% T: 44.6 ± 13.9 C: 30.0 ± 8.4 T: 26.6 ± 11.1 C: 30.6 ± 12.5
Poeschl et al. [59] Residual bone height < 5 mm 7 T: Algae-derived HA + PRP C: Algae-derived HA 96.4% T: 29.0 ± 13.2 C: 22.3 ± 12.3 NR
Raghoebar et al. [60] The mean vertical height of the alveolar bone(mm): 1–3 3 PRP (left or right sinus) NR Non-PRP side: 41.1 ± 8.3 PRP side: 38.4 ± 11.3 NR
Taschieri et al. [61]

Residual Bone Height(mm): T: 2.80 ± 1.04 C: 2.40 ± 1.08

Vital Bone (%): T: 30.70 ± 7.89 C: 22.72 ± 9.21

 6 T: Bio-Oss + P-PRP C: Bio-Oss 100%

T: 30.70 ± 7.89

C: 22.72 ± 9.21

 NR
Tatullo et al. [62] The residual ridge: < 5 mm 3–5 T: DBBM + PRF C: DBBM 100% NR NR
Thor et al. [63]

The mean marginal bone level(mm):

T: 1.3 ± 1.9 C: 1.5 ± 1.7

 18

T: particulated bone mixed + PRP

C: onlay block grafts

 98.7% T:100% C:97.4% NR NR
Thor et al. [31] NR NR T: Autogenous bone + PRP C: Autogenous bone NR T:14 ± 7 C:13 ± 6 NR
Torres et al. [64] Residual crest height < 7 mm 6 T: Bio-Oss + PRP C: Bio-Oss 97.50% T: 30 ± 6 C: 20 ± 4

T: 22 ± 9

C: 28 ± 4
Zhang et al. [65] Residual crest height < 5 mm 6

T: Bio-Oss and PRF

C: Bio-Oss

 NR T: 18.4 ± 5.6 C: 12.9 ± 5.3 NR

CS: calcium sulfate; A-PRF: advanced platelet-rich fibrin; TCP: tricalcium phosphate; CGF: concentrated growth factor; P-PRP: pure platelet-rich plasma; PRGF: platelet-rich growth factor; DBB: deproteinized bovine bone; PRF: Platelet-rich fibrin; USB: Unilab Surgibone; RABH: residual alveolar bone height; β-TCP: beta-tricalcium phosphate; LPRF: leukocyte- and platelet-rich fibrin; DBBM: deproteinized bovine bone mineral; PRP: platelet-rich plasma; PRF: Platelet-rich fibrin; FDBA: freeze-dried bone allograft; ISQ: implant stability quotient; SFE: Sinus floor elevation; T-PRF: titanium-prepared platelet rich fibrin; L-PRF: leukocyte and platelet-rich fibrin